China's medical technology industry is no longer defined simply by low-cost manufacturing.

A growing group of Chinese MedTech companies now develops high-end imaging systems, patient monitors, endoscopes, cardiovascular implants, ophthalmic devices, laboratory diagnostics and surgical robots. Some have built substantial international businesses; others remain more China-focused but are becoming important competitors in technology-intensive markets.

For global MedTech executives, understanding China therefore requires knowing who the companies are, what they actually make, and why they matter.

MedChina selected 20 companies that provide a useful starting point.

This is not a revenue ranking, market-cap ranking or definitive "top 20" list. The companies were selected because of their scale, position in an important medical-device category, international presence, technological significance, or potential to influence competition beyond China.

The list includes both diversified MedTech groups and specialized companies. In vitro diagnostics is included within the scope of MedTech.

20 Chinese MedTech Companies at a Glance

Diversified MedTech and Medical Equipment Companies

Mindray

Headquarters: Shenzhen

Listed: Shenzhen Stock Exchange, 300760

For many international executives, Mindray is the first Chinese company that comes to mind when discussing globally competitive MedTech.

The company has built a broad portfolio covering patient monitoring, anesthesia and critical care, ultrasound and other imaging systems, laboratory diagnostics, AEDs and defibrillation, infusion systems and orthopedics. Its orthopedics business now includes trauma, spine and arthroplasty products.

What makes Mindray particularly important is that its internationalization began much earlier than that of many newer Chinese MedTech companies. Its products and commercial operations now extend across major developed and emerging markets, while acquisitions such as Datascope's patient-monitoring business helped the company build a meaningful position outside China.

In 2026, Mindray is also increasingly presenting itself as a provider of integrated hospital solutions rather than individual pieces of equipment. At major international exhibitions it has emphasized connected ICUs, laboratory automation, imaging, perioperative care and AI-enabled workflows.

Why it matters: Mindray demonstrates that a Chinese medical-equipment company can move from competing primarily on cost to competing on product portfolios, clinical workflow, service networks and global brand recognition.

United Imaging Healthcare

Headquarters: Shanghai

Listed: Shanghai Stock Exchange STAR Market, 688271

United Imaging Healthcare is one of the most important companies to watch if you compete in high-end medical imaging.

Its portfolio includes CT, MRI, PET/CT and other molecular-imaging systems, digital radiography, angiography, mammography, mobile C-arms, radiotherapy equipment and digital solutions.

The company's strategic significance goes beyond its position in China. United Imaging has been building a direct presence in international markets including the United States and Europe and continues to introduce high-end systems globally. By the end of 2024, the company said it had launched more than 140 products globally, including 49 products cleared through the U.S. FDA's 510(k) pathway.

Its overseas business has continued to expand, and in 2026 the company signed a cooperation framework with Bayer covering imaging and digital health.

Why it matters: United Imaging is an example of Chinese competition moving into one of MedTech's most technologically demanding and historically concentrated markets.

For GE HealthCare, Siemens Healthineers, Philips and their suppliers, China is no longer only an important imaging market. It is also the home market of an increasingly international competitor.

WEGO

Headquarters: Weihai, Shandong

Key listed business: WEGO Medical, Hong Kong Stock Exchange, 1066

WEGO developed from a medical-consumables manufacturer into one of China's broadest healthcare manufacturing groups.

Its businesses now span clinical care products, orthopedics, blood purification, pharmaceutical packaging, interventional devices, surgical robots and medical engineering. The group says its portfolio includes more than 1,000 types of medical devices and pharmaceuticals in over 200,000 specifications.

WEGO has also used acquisitions to internationalize. In 2017, the group acquired U.S.-based Argon Medical Devices in an $850 million transaction, expanding its presence in interventional medical products and overseas markets.

The group also participates in surgical robotics through the MicroHand platform.

Why it matters: WEGO represents another important form of Chinese MedTech competitor: a large manufacturing group with extensive product breadth, deep domestic hospital relationships and the ability to expand into higher-value device categories.

MicroPort Scientific

Headquarters: Shanghai

Listed: Hong Kong Stock Exchange, 0853

MicroPort began in coronary intervention but has developed into a diversified international medical-device group.

Its businesses span coronary intervention, orthopedics, cardiac rhythm management, electrophysiology, structural heart disease, neurovascular intervention, aortic and peripheral intervention, surgical robotics and other medical technologies.

According to its 2025 interim reporting, MicroPort products had reached more than 20,000 hospitals in over 100 countries and regions. Its coronary products alone were available in more than 90 countries and regions by 2025.

MicroPort is unusual because several important businesses within its wider ecosystem have themselves become substantial or separately listed companies. Two of them — MicroPort MedBot and Endovastec — appear separately later in this guide because they have become strategically important companies in their own categories.

Why it matters: MicroPort is one of the clearest examples of a Chinese interventional-device company expanding simultaneously through internal R&D, acquisitions, overseas operations and specialized subsidiary platforms.

Lepu Medical

Headquarters: Beijing

Listed: Shenzhen Stock Exchange, 300003

Founded in 1999, Lepu Medical was one of China's early domestic companies focused on interventional cardiology.

Its portfolio has since expanded considerably. It now covers coronary and peripheral intervention, structural heart devices, cardiac rhythm management, critical care, hemodialysis, ECG and patient monitoring, IVD, surgical products, orthopedics and angiography systems.

Lepu has also built an increasingly international operating structure. Its international website describes subsidiaries and local operations in Europe, Brazil and Southeast Asia, while its product portfolio includes numerous CE-certified and FDA-cleared devices.

One area worth watching is Lepu's attempt to combine its traditional cardiovascular strength with newer technologies. Its portfolio includes products in structural heart disease, intravascular lithotripsy, ECG and remote monitoring, among other areas.

Why it matters: Lepu demonstrates how some of China's older cardiovascular-device leaders are evolving from single-category manufacturers into broad medical-technology platforms.

Yuwell Medical

Headquarters: Jiangsu

Listed: Shenzhen Stock Exchange, 002223

Yuwell occupies a different position from companies such as United Imaging or MicroPort.

Its strength is in home healthcare and chronic-disease management, with products spanning respiratory therapy, oxygen therapy, diabetes care, blood-pressure monitoring, AEDs, medical diagnostics and other home and professional medical applications.

That makes Yuwell particularly relevant as healthcare increasingly shifts outside traditional hospital settings.

The company is also increasing its international ambitions. In 2025 it announced a strategic investment and cooperation arrangement with U.S. respiratory-care company Inogen, and in 2026 it made its first appearance at CES in Las Vegas with a portfolio focused on respiratory health, chronic-disease management, emergency care and connected health.

Why it matters: Yuwell is useful to watch for a different reason from high-end imaging or robotics companies: it shows how Chinese MedTech manufacturers are building scale in homecare, respiratory disease and chronic-disease management — markets that may expand as populations age.

Imaging, Endoscopy and Diagnostics

SonoScape

Headquarters: Shenzhen

Listed: Shenzhen Stock Exchange, 300633

SonoScape began with ultrasound and has gradually expanded into endoscopy, minimally invasive surgical imaging and intravascular imaging.

Its current portfolio includes cart-based and portable ultrasound, gastrointestinal endoscopy, endoscopic ultrasound, bronchoscopy, rigid and flexible surgical endoscopy, minimally invasive surgery systems and IVUS.

The company says its products and services are available in more than 170 countries and regions and that it operates seven R&D centers, including facilities in China, Germany, Japan and the United States.

SonoScape is particularly interesting because it has moved beyond the traditional export model for Chinese ultrasound equipment. Its HD-550 gastrointestinal endoscopy system received U.S. FDA 510(k) clearance, while multiple ultrasound and endoscopy products have also obtained European regulatory approvals.

Why it matters: SonoScape is becoming relevant in two markets long dominated by major international brands — ultrasound and flexible endoscopy.

EDAN Instruments

Headquarters: Shenzhen

Listed: Shenzhen Stock Exchange, 300206

EDAN is one of China's long-established exporters of medical equipment.

Its portfolio spans patient monitoring, diagnostic ECG, obstetrics and gynecology, ultrasound, point-of-care testing, in-vitro diagnostics and intelligent healthcare solutions. The company says its products are used in more than 170 countries.

In contrast with highly specialized Chinese startups, EDAN's competitive model has historically relied on a relatively broad equipment portfolio and international distribution.

It is also investing in localization. In 2026 EDAN announced an expansion of its U.S. operations, including additional manufacturing capabilities.

Why it matters: EDAN is a useful reminder that China's globalization in MedTech did not begin with today's surgical-robot and cardiovascular startups. A group of equipment manufacturers has spent decades building distributor networks and local operations abroad.

Autobio Diagnostics

Headquarters: Zhengzhou

Listed: Shanghai Stock Exchange, 603658

Autobio is one of China's major laboratory-diagnostics companies.

Its core fields include immunoassay, microbiology, clinical chemistry and molecular diagnostics, with an increasing emphasis on integrated laboratory solutions and automation.

The company says its products are exported to more than 100 countries. It has also accumulated a substantial number of overseas regulatory registrations and has been increasing its participation in international laboratory-medicine events and scientific collaborations.

Autobio is especially important in understanding China's IVD industry because Chinese competition is gradually moving from individual reagents or instruments toward complete laboratory platforms, including automation, core reagents, analyzers and software.

Why it matters: For multinational diagnostics companies, the long-term competitive question in China is increasingly about complete laboratory ecosystems rather than isolated low-cost tests.

Wondfo Biotech

Headquarters: Guangzhou

Listed: Shenzhen Stock Exchange, 300482

Wondfo is best known internationally for point-of-care diagnostics, but the company has been expanding beyond rapid tests.

Its current technology platforms include colloidal-gold testing, fluorescence immunoassay, chemiluminescence, coagulation, blood gas, molecular diagnostics, pathology and HPLC hemoglobin testing.

Wondfo reported 2025 revenue of RMB2.087 billion. During 2025–2026 it continued to build localized operations overseas, including a wholly owned subsidiary in the Philippines and expansion into more advanced diagnostic products.

Why it matters: Wondfo shows how Chinese POCT companies are attempting to move up the diagnostic value chain — from inexpensive rapid testing toward instruments, laboratory platforms, pathology and molecular diagnostics.

Aohua Endoscopy

Headquarters: Shanghai

Listed: Shanghai Stock Exchange STAR Market, 688212

Aohua is one of China's most important domestic flexible-endoscopy manufacturers.

The company develops electronic endoscopy systems, video endoscopes and related peripheral devices and consumables. It has been publicly listed on Shanghai's STAR Market since 2021.

For decades, the global gastrointestinal endoscopy market has been characterized by a relatively concentrated group of Japanese suppliers. The emergence of companies such as Aohua and SonoScape therefore has strategic significance beyond their present revenue.

China is one of the world's largest endoscopy markets, giving domestic manufacturers a substantial clinical and commercial base from which to improve products and develop new generations of systems.

Why it matters: Aohua is a company to watch if Chinese manufacturers begin to alter the competitive structure of the global flexible-endoscopy market.

Eyebright Medical

Headquarters: Beijing

Listed: Shanghai Stock Exchange STAR Market, 688050

Eyebright Medical is an ophthalmic-device company whose portfolio extends across three areas: surgical treatment, myopia management and consumer vision care.

Its major product categories include intraocular lenses, orthokeratology lenses and soft contact lenses, while its broader pipeline extends into additional ophthalmic surgical and vision-correction products.

The combination is strategically interesting. China has a very large cataract-surgery market and an unusually large population receiving myopia-management products. Eyebright therefore participates simultaneously in hospital ophthalmology and consumer-facing vision care.

The company has also been pursuing internationalization, including participation in major international ophthalmology meetings and expansion of its overseas business structure.

Why it matters: Eyebright provides a useful window into the emergence of domestic Chinese competitors in ophthalmic implants and vision-care devices — sectors historically dominated by multinational companies.

Cardiovascular and Interventional Specialists

LifeTech Scientific

Headquarters: Shenzhen

Listed: Hong Kong Stock Exchange, 1302

LifeTech Scientific specializes in minimally invasive cardiovascular and peripheral vascular devices.

Its product portfolio includes structural heart and peripheral vascular solutions, with products such as congenital-heart occluders, left atrial appendage closure systems and vascular intervention devices.

LifeTech is notable for having pursued international markets relatively early. In 2024 the company reported that international business increased 26%, and its 2025 results continued to emphasize overseas expansion.

It has also maintained a long-standing strategic relationship with Medtronic in selected areas, illustrating that Chinese MedTech companies can simultaneously be competitors, suppliers and partners to multinational manufacturers.

Why it matters: LifeTech is an example of a specialized Chinese cardiovascular company that has already progressed well beyond the domestic-market-only stage.

Venus Medtech

Headquarters: Hangzhou

Listed: Hong Kong Stock Exchange, 2500

Venus Medtech is one of China's best-known structural-heart companies.

Its portfolio and pipeline cover all four heart-valve positions — aortic, pulmonary, mitral and tricuspid — as well as related structural-heart technologies.

The company was an early Chinese participant in transcatheter aortic valve replacement and has subsequently pursued an increasingly global technology strategy. Its VenusP-Valve transcatheter pulmonary valve has obtained CE marking, while acquisitions and international R&D activities have expanded the company's exposure to mitral and tricuspid technologies.

Why it matters: Venus illustrates an important evolution in China's cardiovascular industry: companies that first developed products for China's domestic structural-heart market are increasingly building technology portfolios intended for global competition.

Endovastec

Headquarters: Shanghai

Listed: Shanghai Stock Exchange STAR Market, 688016

Endovastec focuses on aortic, peripheral vascular and tumor intervention.

Its major products include thoracic and abdominal aortic stent grafts, surgical stent grafts, peripheral vascular stents, drug-coated balloons and related interventional devices.

In 2025, Endovastec reported revenue of RMB1.351 billion. The company has also been accelerating its international expansion through overseas registrations and acquisitions. In 2024 it completed the acquisition of a European aortic-device business associated with Lombard Medical, adding established endovascular aneurysm repair technologies to its portfolio.

In Feb 2026, one of Endovastec's products also received U.S. FDA Breakthrough Device designation.

Why it matters: Endovastec is particularly relevant to global companies in aortic intervention because it combines a strong domestic position with a deliberate effort to acquire international technology, regulatory assets and commercial channels.

Peijia Medical

Headquarters: Suzhou

Listed: Hong Kong Stock Exchange, 9996

Peijia Medical has built its strategy around two high-value interventional fields: structural heart disease and neurovascular intervention.

Its current portfolio covers transcatheter heart valves as well as products for hemorrhagic stroke, ischemic stroke and neurovascular access. The company currently reports 29 commercialized products across its businesses.

Peijia has also used international partnerships and investments to expand its structural-heart technology base. In 2026, for example, developments associated with JenaValve and HighLife continued to advance its exposure to technologies for aortic regurgitation and mitral valve disease.

Why it matters: Peijia is worth watching because it combines two of China's most active high-value consumable markets and is using a mixture of internal development and international collaboration to build its pipeline.

Surgical Robotics

Surgical robotics deserves its own section.

China now has a large number of medical-robotics companies, but four companies are particularly useful for international readers to understand because they represent different stages and competitive strategies.

TINAVI

Headquarters: Beijing

Listed: Shanghai Stock Exchange STAR Market, 688277

TINAVI is one of China's earliest commercial surgical-robot companies.

Its history in orthopedic robotics dates back to 2005. Its TiRobot systems are designed for orthopedic procedures including spine and trauma surgery, with robotic navigation and positioning used to guide surgical instruments and implants.

The company has accumulated extensive clinical experience in China. Its internationalization has also begun: the TiRobot orthopedic surgical robot obtained European CE MDR certification in 2024.

Why it matters: TINAVI represents China's first generation of commercial surgical-robot companies and gives international observers a useful reference point for how long the Chinese robotics industry has actually been developing.

MicroPort MedBot

Headquarters: Shanghai

Listed: Hong Kong Stock Exchange, 2252

MicroPort MedBot has developed one of the broadest surgical-robot portfolios among Chinese companies.

Its programs cover laparoscopic surgery as well as orthopedic, vascular, natural-orifice and percutaneous intervention applications.

Its flagship Toumai laparoscopic surgical robot has become particularly important to watch because of its overseas expansion.

By February 2026, MicroPort MedBot said Toumai had exceeded 200 global commercial orders across nearly 50 countries and regions, with close to 130 systems commercially installed.

The company is also developing remote-surgery capabilities and has obtained market approvals for remote surgical applications in multiple countries.

Why it matters: Among Chinese laparoscopic surgical-robot companies, MicroPort MedBot has produced some of the clearest evidence so far that international commercialization can become a material part of the business rather than a future aspiration.

Edge Medical

Headquarters: Shenzhen

Listed: Hong Kong Stock Exchange, 2675

Edge Medical is one of China's fastest-growing surgical-robot companies.

Its portfolio includes multi-port laparoscopic surgical robots, single-port systems and natural-orifice robotic platforms.

The company has been particularly active in single-port robotics. Its SP1000 single-port platform has been approved in China for multiple clinical specialties, while Edge has continued to develop its next-generation systems and remote-surgery platform.

Edge's international regulatory strategy is also advancing. Its single-port platform and combined multi-/single-port robotic platform received CE certification in 2025. The company listed on the Hong Kong Stock Exchange in January 2026.

Why it matters: Edge is important because Chinese competition in robotic surgery is no longer confined to conventional multi-port systems. Domestic companies are already competing across multi-port, single-port, remote and natural-orifice architectures.

Cornerstone Robotics

Headquarters: Hong Kong

Private company

Cornerstone Robotics was established in 2019 and develops the Sentire endoscopic surgical robotic system.

The company says it operates three global R&D hubs and six business centers and has built a 30,000-square-meter manufacturing facility in China. Its surgical robotic system is developed in-house with a high degree of vertical integration.

Cornerstone is particularly interesting because it has pursued mainland China and international markets almost simultaneously.

Its Sentire system has received NMPA approval in China. In May 2026, the system also received CE MDR certification in Europe and regulatory clearance from Singapore's Health Sciences Authority.

The company is headquartered in Hong Kong, with operations and manufacturing capabilities extending into Shenzhen and other markets.

Why it matters: Cornerstone represents a newer generation of Chinese surgical-robot companies that are being designed as international businesses from an early stage rather than following a long sequence of China first and overseas later.

What These 20 Companies Tell Us About Chinese MedTech

Looking at these companies together reveals several changes that are more important than any individual corporate story.

China's strongest MedTech companies are no longer concentrated in low- or mid-end products

The list now includes companies developing 5T MRI systems, PET/CT, robotic surgery platforms, transcatheter valves, aortic stent grafts, advanced endoscopy systems, automated laboratories and ophthalmic implants.

That changes the nature of competition.

For multinational companies, Chinese competitors increasingly overlap with product categories that historically had high technological and regulatory barriers.

There is no single model for a "Chinese MedTech company"

Mindray and MicroPort are diversified platforms.

United Imaging is concentrated around high-end imaging and radiotherapy.

Autobio and Wondfo come from diagnostics.

Venus, Endovastec and Peijia grew from highly specialized interventional fields.

TINAVI, Edge, MicroPort MedBot and Cornerstone represent different generations of surgical-robot companies.

Yuwell focuses much more heavily on home medical care and chronic-disease management.

That diversity matters. The emergence of Chinese MedTech should not be interpreted as one homogeneous wave of inexpensive manufacturers entering international markets.

Internationalization is entering a new stage

Older Chinese medical-device exporters generally expanded through overseas distributors.

That model still matters, but the leading companies are increasingly adding:

• overseas subsidiaries;

• local service teams;

• international manufacturing;

• acquisitions;

• overseas R&D centers;

• international clinical trials;

• FDA, CE MDR and other regulatory registrations;

• partnerships with multinational companies.

United Imaging is selling sophisticated imaging systems internationally. MicroPort has products in more than 100 countries and regions. SonoScape and EDAN have extensive overseas distribution. MicroPort MedBot is already reporting substantial international surgical-robot orders. Cornerstone is pursuing Europe and Asia at an early stage of commercialization.

For global MedTech executives, the competitive implications therefore extend beyond China itself.

China is becoming both a market and a development base

The traditional multinational-company model treated China primarily as a sales market and manufacturing location.

That framework is becoming incomplete.

China now contains large clinical markets, extensive engineering capabilities, local supply chains, increasingly sophisticated domestic competitors and a growing pool of companies using China as the base from which they develop products for global markets.

This is particularly visible in surgical robotics, cardiovascular intervention, imaging, endoscopy and diagnostics.

The strategic question is therefore changing.

For many product categories, it is no longer enough to ask:

Who are our competitors in China?

Global companies increasingly also need to ask:

Which Chinese companies could become our competitors in Europe, Southeast Asia, Latin America, the Middle East or eventually the United States?

That is one of the most important questions in global MedTech over the next decade.

August 18, 2026